New drugs and targets in haematological malignancies

Mutant-specific kinase inhibitors and TAT highlights

Drugging the cancer genome to overcome drug resistance

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma

Combination of pazopanib and paclitaxel safe in urothelial cancer

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction

mRCC: Are we doing all we can to manage adverse events?

mRCC: Real-world experience: achieving efficacy beyond clinical trials

mRCC: Understanding the patient's perspective

mRCC: Closing remarks